The pace of approvals for abbreviated new drug applications (ANDAs) by the US drug regulator has halved, compared to pre-Covid levels, revealed the latest data from India Ratings & Research (Ind-Ra).
Compared to 670 global ANDA approvals given by the US Food and Drug Administration (USFDA) in the first half (H1) of calendar year 2019, the number of approvals has halved to 328 in H12021 (calendar).
Within this, the ANDA approvals secured by Indian pharmaceutical (pharma) firms have fallen from 267 in H12019 (calendar) to 137 in H12021 (calendar) - a 49-per cent drop.
India’s share in the global ANDA